Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation

被引:115
作者
Chien, JY [1 ]
Friedrich, S [1 ]
Heathman, MA [1 ]
de Alwis, DP [1 ]
Sinha, V [1 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
drug development; modeling and simulation; pharmacokinetics/pharmacodynamics; NONMEM; design optimization;
D O I
10.1208/aapsj070355
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacokinetic (PK) and pharmacodynamic (PD) modeling and simulation (M&S) are well-recognized powerful tools that enable effective implementation of the learn-and-confirm paradigm in drug development. The impact of PK/PD M&S on decision making and drug development risk management is dependent on the question being asked and on the availability and quality of data accessible at a particular stage of drug development. For instance, M&S methodologies can be used to capture uncertainty and use the expected variability in PK/PD data generated in pre-clinical species for projection of the plausible range of clinical dose; clinical trial simulation can be used to forecast the probability of achieving a target response in patients based on information obtained in early phases of development. Framing the right question and capturing the key assumptions are critical components of the learn-and-confirm" paradigm in the drug development process and are essential to delivering high-value PK/PD M&S results. Selected works of PK/PD modeling and simulation from preclinical to phase III are presented as case examples in this article. Copyright ©2003. All Rights Reserved."
引用
收藏
页码:E544 / E559
页数:16
相关论文
共 28 条
[1]   Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979) [J].
Callies, S ;
de Alwis, DP ;
Mehta, A ;
Burgess, M ;
Aarons, L .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (01) :39-48
[2]   A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979) [J].
Callies, S ;
de Alwis, DP ;
Wright, JG ;
Sandler, A ;
Burgess, M ;
Aarons, L .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (02) :107-118
[3]   Considerations in the design and development of transport inhibitors as adjuncts to drug therapy [J].
Dantzig, AH ;
de Alwis, DP ;
Burgess, M .
ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (01) :133-150
[4]   Optimal design of a population pharmacodynamic experiment for ivabradine [J].
Duffull, SB ;
Mentré, F ;
Aarons, L .
PHARMACEUTICAL RESEARCH, 2001, 18 (01) :83-89
[5]   EXPERIMENTAL-DESIGN AND EFFICIENT PARAMETER-ESTIMATION IN PRECLINICAL PHARMACOKINETIC STUDIES [J].
ETTE, EI ;
HOWIE, CA ;
KELMAN, AW ;
WHITING, B .
PHARMACEUTICAL RESEARCH, 1995, 12 (05) :729-737
[6]  
Galluppi Gerald R., 2001, Clinical Pharmacology and Therapeutics, V69, P387, DOI 10.1067/mcp.2001.115455
[7]  
Giaccone G, 1997, CLIN CANCER RES, V3, P2005
[8]   Use of prior information to stabilize a population data analysis [J].
Gisleskog, PO ;
Karlsson, MO ;
Beal, SL .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2002, 29 (5-6) :473-505
[9]   Simulation of clinical trials [J].
Holford, NHG ;
Kimko, HC ;
Monteleone, JPR ;
Peck, CC .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2000, 40 :209-234
[10]   THE EFFECT OF QUINIDINE AND ITS METABOLITES ON THE ELECTROCARDIOGRAM AND SYSTOLIC-TIME INTERVALS - CONCENTRATION - EFFECT RELATIONSHIPS [J].
HOLFORD, NHG ;
COATES, PE ;
GUENTERT, TW ;
RIEGELMAN, S ;
SHEINER, LB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 11 (02) :187-195